BioSpace News Archive

Oncology Pharma Inc. is pleased to announce that it has completed the initial feasibility phase of its licensed dactinomycin nanoemulsion.

Baudax Bio, Inc. announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the Noble Capital Markets’ 18th Annual Investor Conference, taking place in Hollywood, Florida on Wednesday, April 20, 2022, at 3:30 p.m. Eastern Time.

Recce Pharmaceuticals Ltd. (ASX:RCE, FSE:R9Q) (the Company), the company developing a new class of synthetic anti-infectives, is pleased to report an Independent Safety Committee data review of 10 healthy human subjects dosed in a Phase I intravenous (IV) clinical trial of RECCE® 327 (R327), demonstrating good safety and tolerability at 1,000mg.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT™, for the treatment of metastatic breast cancer (breast cancer that has spread beyond the breast).

Molecular Targeting Technologies Inc. and ITM Isotope Technologies Munich SE announced the signing of a global clinical supply agreement that provides MTTI with ITM’s medical radioisotope no-carrier-added lutetium-177 for the preclinical and clinical development as well as potential commercial production of MTTI’s radiopharmaceutical candidate n.c.a.

Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today presents long-term safety and efficacy data from the 2nd year open-label extension (OLE) of its global Phase 3 OPTIMAL clinical trial that compared Mycapssa® (octreotide capsules) to placebo for maintenance of biochemical response in patients with acromegaly.

CollPlant today announced that Dr. Jasmine Seror, CollPlant’s Head of Aesthetic Medicine and Exploratory Products, will deliver a presentation at the Aesthetics Innovation Summit 2022, to be held in San Diego, California, on Wednesday, April 20, 2022.

Lyra Therapeutics, Inc. today announced the closing of its previously announced private placement of common stock (or, in lieu thereof, pre-funded warrants to purchase common stock), resulting in gross proceeds of approximately $100.5 million.

Coeptis Therapeutics, Inc. today announced that the Company has entered into a strategic agreement with Statera Biopharma, Inc.

EdiGene, Inc. said it has entered into a research collaboration with Peking University Cancer Hospital to understand gene mutation frequency and clinicopathologic features of patients with advanced colorectal cancer in China.